Intravesical gemcitabine for non-muscle invasive bladder cancer: An abridged Cochrane Review.
Mi-Ah HanPhilipp MaischJae Hung JungJun Eul HwangVikram M NarayanAnne ClevesEu Chang HwangPhilippe D ViolettePublished in: Investigative and clinical urology (2022)
Based on the findings of this review, gemcitabine may have a favorable impact on recurrence and progression-free survival than saline and mitomycin but we are uncertain about how major adverse events compare. The same is true when comparing gemcitabine to BCG in individuals with high-risk diseases who have previously failed BCG.